Biotech entity

CRISPR-Cas9

Technology

gene-therapy is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Asian Elephant, the most common co-covered peer. Each carries 4 original sources on average. We currently track 1 Biotech story that mention CRISPR-Cas9, all published on March 4, 2026.

Last mentioned: Mar 4, 2026

Entity pulse

Recent coverage · CRISPR-Cas9

1 story
7 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about CRISPR-Cas9

gene-therapy is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Asian Elephant, the most common co-covered peer. Each carries 4 original sources on average. We currently track 1 Biotech story that mention CRISPR-Cas9, all published on March 4, 2026.

Stories tracked
1
Sources per story
4

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering CRISPR-Cas9. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Target Birth Date

    Projected window for the birth of the first mammoth-elephant hybrid calf.

  2. Dubai Biovault

    Colossal announces the opening of a major genetic preservation facility in Dubai.

  3. Series B Funding

    Total funding surpasses $225M, valuing the company at over $1 billion.

  4. Dodo Project Announced

    The company expands its portfolio to include the de-extinction of the dodo bird.

  5. Company Launch

    Colossal Biosciences officially launches with $15M in seed funding to revive the woolly mammoth.

Stories mentioning CRISPR-Cas9 1

Gene & Cell Therapy Neutral

Colossal Biosciences Faces Ethical Scrutiny Over Mammoth De-Extinction Goals

Colossal Biosciences is advancing its ambitious plan to 'de-extinct' the woolly mammoth using CRISPR technology, sparking intense debate over ecological ethics and resource allocation. While the company frames the project as a climate solution, critics argue it distracts from urgent conservation efforts for existing endangered species.

4 sources

Source: iowapublicradio.org · wdiy.org

CRISPR-Cas9 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.